MelanA (MLANA) Mouse Monoclonal Antibody [Clone ID: M2-7C10]
CAT#: AM32812PU-T
MelanA (MLANA) mouse monoclonal antibody, clone M2-7C10, Purified
Size: 100 ug
Need it in bulk or conjugated?
Get a free quote
CNY 3,223.00
货期*
5周
规格
Cited in 5 publications. |
Specifications
Product Data | |
Clone Name | M2-7C10 |
Applications | FC, IF, IHC, IP, WB |
Recommend Dilution | ELISA: Use Antibody without BSA for Coating. Western Blot: 0.5-1 µg/ml. Immunoprecipitaion: 1-2 µg/500 µg protein lysate. Flow Cytometry: 0.5-1 µg/106 cells. Immunofluorescence: 1-2 µg/ml. Immunohistochemistry on Frozen Sections. Immunohistochemistry on Paraffin Sections: 0.5-1 µg/ml for 30 minutes at RT. Staining of formalin-fixed tissues is enhanced by boiling tissue sections in 10 mM citrate buffer, pH 6.0 for 10-20 min followed by cooling at RT for 20 min. Positive Control: SK-MEL-13 and SK-MEL-19 Melanoma cell lines; Melanomas. |
Reactivity | Human |
Host | Mouse |
Clonality | Monoclonal |
Immunogen | Recombinant Human MART-1 protein. |
Specificity | This MART-1 antibody clone M2-7C10 recognizes a protein doublet of 20-22kDa, identified as MART-1 (Melanoma Antigen Recognized by T cells 1) or Melan-A. This MART-1 antibody clone M2-7C10 does not react with Mouse or Rat. Others species not tested. Researchers should use the MART-1 Antibody clone M2-9E3 (Cat.-No AM32813PU), which also recognizes Human MART-1, to detect Mouse or Rat MART-1. The clone M2-7C10 MART-1 antibody labels melanomas and other tumors showing melanocyte differentiation, and is widely used for assessing melanomas (Campoli, 2012, Ohsie, 2012, Collins, 2012). Analysis of melanoma lesions with this antibody shows that there is significant heterogeneity of expression of MART-1 both as a percentage of cells and in intensity of expression (Marincola, 1996). The reactivity of the MART-1 antibody is not restricted to melanoma, and the antibody has also been shown to label some mesenchymal tumors and sarcomas (Campoli, 2012). The exact eptiope recognized by this MART-1 antibody has not been mapped. However, the MART-1 epitope recognized by this antibody appears to be different from that recognized by the MART-1 antibody clone M2-9E3 (Cat.-No AM32813PU) (Kawakami, 1997). Researchers often use more than one antibody against a given specificity to help follow up and validate results. Hence, it may be useful to use both the Cat.-No AM32812PU and Cat.-No AM32813PU antibodies in parallel to obtain additional information about MART-1 expression. Cellular Localization: Cytoplasmic. |
Formulation | 10mM PBS State: Purified State: Liquid purified IgG fraction from Bioreactor Concentrate Stabilizer: 0.05% BSA Preservative: 0.05% Sodium Azide |
Concentration | lot specific |
Purification | Affinity Chromatography on Protein A/G |
Conjugation | Unconjugated |
Storage Condition | Store undiluted at 2-8°C. |
Predicted Protein Size | 20-22 kDa (Doublet) |
Gene Name | melan-A |
Database Link | |
Background | MART-1 (Melanoma Antigen Recognize by T cells 1), also known as Melan-A, is an 18 kDa melanocyte differentiation antigen recognized by autologous cytotoxic T lymphocytes. MART-1 is expressed in melanosomes and the endoplasmic reticulum. MART-1 is the most widely used marker for identifying malignant melanoma, the most deadly form of skin cancer, and facilitating complete removal of the primary tumor (Campoli, 2012). In this regard, MART-1 is used both as a confirmatory marker for melanocyte differentiation in S100 (protein present in melanocytes) positive lesions and a primary marker to evaluate the extent of melanocyte tumors (Ohsie, 2012, Collins, 2012). MART-1 specific monoclonal antibodies have high sensitivity (75-92%) and specificity (95-100%) for melanoma (Campoli, 2012, Oshie et.al, 2012). |
Synonyms | Melan-A protein, MLANA, Antigen SK29-AA, LB39-AA, MelanA, MART1 |
Reference Data |
Citations (5)
The use of this Antibodies has been cited in the following citations: |
---|
Incidentally discovered distant cutaneous metastasis of sacral chordoma: a case with variation in S100 protein expression (compared to the primary tumor) and review of the literature
,Collins GR, Essary L, Strauss J, Hino P, Cockerell CJ,
J. Cutan. Pathol.
,PubMed ID 22524546
[MLANA]
|
Tumor cell plasticity and angiogenesis in human melanomas
,Mihic-Probst D, Ikenberg K, Tinguely M, Schraml P, Behnke S, Seifert B, Civenni G, Sommer L, Moch H, Dummer R,
PLoS ONE
,PubMed ID 22442699
[MLANA]
|
MART-1 is required for the function of the melanosomal matrix protein PMEL17/GP100 and the maturation of melanosomes
,Hoashi T, Watabe H, Muller J, Yamaguchi Y, Vieira WD, Hearing VJ,
J. Biol. Chem.
,PubMed ID 15695812
[MLANA]
|
Analysis of expression of the melanoma-associated antigens MART-1 and gp100 in metastatic melanoma cell lines and in in situ lesions
,Marincola FM, Hijazi YM, Fetsch P, Salgaller ML, Rivoltini L, Cormier J, Simonis TB, Duray PH, Herlyn M, Kawakami Y, Rosenberg SA,
J Immunother Emphasis Tumor Immunol
,PubMed ID 8811494
[MLANA]
|
Production of recombinant MART-1 proteins and specific antiMART-1 polyclonal and monoclonal antibodies: use in the characterization of the human melanoma antigen MART-1
,Kawakami Y, Battles JK, Kobayashi T, Ennis W, Wang X, Tupesis JP, Marincola FM, Robbins PF, Hearing VJ, Gonda MA, Rosenberg SA,
J. Immunol. Methods
,PubMed ID 9075767
[MLANA]
|
Documents
Product Manuals |
FAQs |
SDS |
Resources
抗体相关资料 |
Customer
Reviews
Loading...